Table 2: Significant Observations in Host Modulation
Prostaglandins are found to be important mediators of bone resorption.
The mechanism of aspirin’s effect on the body is discovered to be through the inhibition of prostaglandins.
Prostaglandins are proposed to be major mediators of periodontal bone loss.
Inhibitors of prostaglandins (eg, aspirinlike drugs) are proposed to be studied as a way of blocking periodontal bone loss
Indomethacin is found to inhibit ligature-induced bone loss in beagles.
Flurbiprofen is found to inhibit naturally occurring periodontal diseases in beagles.
Flurbiprofen significantly blocks the bone loss of human periodontal diseases.
Subantimicrobial dose doxycycline, which blocks matrix metalloproteinases, blocks human periodontal diseases.
Triclosan is found to be anti-inflammatory, as well as antimicrobial.
Host modulation strategies are viewed as an important treatment strategy for patients with periodontal diseases.
4 times daily) between 6 and 12 weeks.The findings of this study
participated and applied randomized dentifrice formulations
indicated that mechanical scaling plus acetylsalicylic acid result-
(0.3%, 1%, or 3% ketoprofen vs placebo) twice daily. Although
ed in synergistic reductions in gingival inflammation, probing
intergroup differences in bone loss rates approached signifi-
pocket depth, and clinical attachment loss.22
cance (P = .06) in the trial, significant strata-by-treatment
In the mid-1990s, investigators began to examine the effect
interactions were detected such that patients with advanced
of topical NSAID formulations on periodontal diseases in hu-
periodontitis dosing with 1% or 3% (S)-ketoprofen demon-
man clinical trials. Heasman et al23,24 clinically and radiograph-
strated comparatively greater improvements in disease progres-
ically studied 49 adult periodontitis patients randomized for
sion.25 In summary, a great deal of evidence gathered from
adjunctive topical flurbiprofen or placebo gels. All patients
preclinical and clinical studies since the late 1970s indicates that
received conventional nonsurgical periodontal therapy at base-
it is possible to inhibit periodontal disease progression via the
line. Over the subsequent 12 months of topical dosing, no clin-
local modulation of arachidonic acid metabolites with NSAIDs
ical effects of flurbiprofen on plaque and bleeding scores, prob-
(Table 2). Serhan et al26 described a novel series of oxygenated
ing depths, and attachment levels were observed; however,
arachidonic-acid derivatives called lipoxygenase interaction
significantly more sites in the flurbiprofen-treated group ex-
products or lipoxins. These derivatives (eg, lipoxin A4 and li-
hibited bone gain when compared with the placebo group. In a
poxin B4) arise via 15- or 5-lipoxygenase activities and by cell-
55-patient clinical trial, Jeffcoat and colleagues21 assessed the
to-cell interactions, and appear to serve as endogenous anti-
efficacy of a topical NSAID rinse, ketorolac tromethamine, for
inflammatory mediators.26 Hasturk et al27 reported that these
treating adult periodontitis. At baseline, patients were random-
aspirin-induced lipoxins block ligature-induced bone loss in
ized for 0.1% ketorolac rinse plus peroral placebo capsule, pla-
cebo rinse plus peroral 50-mg flurbiprofen capsule, or placeborinse and placebo peroral capsule. Patients were monitored
radiographically, clinically, and biochemically over a 6-month
period during which they administered rinses and capsules
Host cytokines are another group of inflammatory mediators
twice daily. Although no significant differences among the
highly implicated in periodontal disease pathogenesis and in-
groups were detected for clinical parameters, patients treated
tensely investigated as potential chemotherapeutic targets. Cy-
with topical ketorolac or systemic flurbiprofen exhibited signif-
tokines, literally “cell proteins” in etymology, transmit infor-
icantly reduced alveolar bone loss rates and depressed pro-
mation from one cell to another via autocrine or paracrine
staglandin E2 levels in gingival crevicular fluid as compared
mechanisms. Following specific binding to their complementary
with patients treated with placebo. Paquette and colleagues25
receptors, proinflammatory cytokines like interleukin-1 (IL-1)
conducted a 12-month clinical trial evaluating the clinical effi-
and tumor necrosis factor (TNF) trigger intracellular signaling
cacy of topical (S)-ketoprofen dentifrices. Ninety six patients
events and catabolic cell behaviors.
DENTISTRY INDIA—NOVEMBER | DECEMBER 2008
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
Personal History Name: ____________________________________________ Birth date: ____________Nickname or other names you go by: _________________________________________Marital Status:Single ___ Married___ Separated____ Divorced ____ Remarried ____ Partner _____ PRESENT LIVING SITUATIONS: Where do you live:House___ Apartment ____ Room ____ Hotel ____Other (Specify) ________________Do you